학술논문
Characteristics and outcome of ambulatory heart failure patients receiving a left ventricular assist device
Document Type
article
Author
Guillaume Baudry; Nicolas Nesseler; Erwan Flecher; André Vincentelli; Céline Goeminne; Clément Delmas; Jean Porterie; Karine Nubret; Mathieu Pernot; Michel Kindo; Tam Hoang Minh; Philippe Rouvière; Philippe Gaudard; Magali Michel; Thomas Senage; Aude Boignard; Olivier Chavanon; Marylou Para; Constance Verdonk; Edeline Pelcé; Vlad Gariboldi; Frederic Anselme; Pierre‐Yves Litzler; Katrien Blanchart; Gerard Babatasi; Marie Bielefeld; Olivier Bouchot; David Hamon; Nicolas Lellouche; Xavier Bailleul; Thibaud Genet; Romain Eschalier; Nicolas d'Ostrevy; Marie‐Cécile Bories; Ramzi Abi Akar; Hugues Blangy; Fabrice Vanhuyse; Jean François Obadia; Vincent Galand; Matteo Pozzi
Source
ESC Heart Failure, Vol 8, Iss 6, Pp 5159-5167 (2021)
Subject
Language
English
ISSN
2055-5822
Abstract
Abstract Aims Despite regularly updated guidelines, there is still a delay in referral of advanced heart failure patients to mechanical circulatory support and transplant centres. We aimed to analyse characteristics and outcome of non‐inotrope‐dependent patients implanted with a left ventricular assist device (LVAD). Methods and results The ASSIST‐ICD registry collected LVAD data in 19 centres in France between February 2006 and December 2016. We used data of patients in Interagency Registry for Mechanically Assisted Circulatory Support Classes 4–7. The primary endpoint was survival analysis. Predictors of mortality were searched with multivariable analyses. A total of 303 patients (mean age 61.0 ± 9.9 years, male sex 86.8%) were included in the present analysis. Ischaemic cardiomyopathy was the leading heart failure aetiology (64%), and bridge to transplantation was the main implantation strategy (56.1%). The overall likelihood of being alive while on LVAD support or having a transplant at 1, 2, 3, and 5 years was 66%, 61.7%, 58.7%, and 55.1%, respectively. Age [hazard ratio (HR) 1.03, 95% confidence interval (CI) 1.00–1.05; P = 0.02], a concomitant procedure (HR 2.32, 95% CI 1.52–3.53; P